But this strategy may involve another controversial mechanism independent from NMDARs, which is associated with nicotinic acetylcholine receptors (nAChRs): KYNA is also a non-competitive antagonist of the α7nAChR and the decreased KYNA can reverse α7nAChRs dysfunction in schizophrenia (Albuquerque and Schwarcz, 2013; Plitman et al., 2017). Here, CHRNA7 is linked to schizophrenia.